Keyphrases
Ranitidine
100%
B Cells
100%
T Cells
100%
Histamine Receptor 2
100%
Treatment Cessation
50%
Clinical Benefit
25%
Vaccination
25%
High Dose
25%
Leukopenia
25%
Single Center
25%
Immune Cells
25%
Neutrophils
25%
Eosinophils
25%
Basophils
25%
Neutropenia
25%
Immunoblot Analysis
25%
Immune Parameters
25%
Interleukin-2
25%
Gastrointestinal Tract
25%
Peripheral Blood
25%
Gastroesophageal Reflux Disease
25%
Drug Adverse Events
25%
Duodenal Ulcer
25%
Myelosuppression
25%
Mediation Analysis
25%
Serum Levels
25%
Immunomodulatory Effect
25%
Immunomodulatory
25%
CD25
25%
Clinical Reports
25%
Soluble interleukin-2 Receptor (sIL-2R)
25%
Sustained Impact
25%
Immunology and Microbiology
T Cell
100%
Normal Human
100%
B Cell
100%
Histamine
100%
Vaccination Policy
50%
Blood Level
50%
Drug Megadose
50%
Mediator
50%
Immunocompetent Cell
50%
Immunotherapy
50%
Arm
50%
Basophil Granulocyte
50%
Neutrophil Granulocyte
50%
Eosinophil Granulocyte
50%
Gastrointestinal Tract
50%
CD25
50%
Pharmacology, Toxicology and Pharmaceutical Science
Ranitidine
100%
Normal Human
100%
Histamine H2 Receptor
100%
Malignant Neoplasm
25%
Adverse Event
25%
Vaccination Policy
25%
Clinical Study
25%
Leukopenia
25%
Immunotherapy
25%
Neutropenia
25%
Gastroesophageal Reflux
25%
Bone Marrow Suppression
25%
Duodenum Ulcer
25%